Procaps Enters into Agreement with BDR Pharmaceuticals to Expand Oncology Portfolio in Latin America

Latin American health and pharma company Procaps Group (NASDAQ: PROC) last month entered into an agreement with BDR Pharmaceuticals International Pvt. Limited for 27 oncology molecules for Latin America, including 20 TKIs (Tirosyne Kinase Inhibitors).

Under the agreement, Procaps is responsible for registration, branding, marketing and commercialization throughout Latin America.

Procaps submitted an initial set of 8 molecules to the regulatory authority in Colombia, and intends to later expand in other parts of Latin America.

“These molecules are indicated for different types of cancer such as breast cancer, colon cancer, and chronic myeloid leukemia, among others,” said Dr. Camilo Camacho, COO of Procaps Group, in a statement. “Many of these molecules, if approved, will likely be introduced to our region for the first time, which aligns with our mission to continue to seek to provide patients in Latin America with potential alternative and accessible therapies.”

According to Procaps, the areas within Latin America where it operates have a population of more than 200 million people, and the incidence of cancer affects around 0.3% of the population in these locations, which equates to some 500,000 new cases per year.

“We are very excited to expand our oncology portfolio in the region and add more partner companies and potentially broaden cancer treatment options with several new molecules to better serve more patients and physicians with this serious and growing disease,” added Ruben Minski, CEO of Procaps Group.